Get to know our clinical trials
A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti¿PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
EL OBJETIVO O FINALIDAD DE ESTE ENSAYO CLÍNICO ES PROBAR UN FÁRMACO EXPERIMENTAL LLAMADO GS-1811 SOLO, GS-1811 EN COMBINACIÓN CON ZIMBERELIMAB (TAMBIÉN CONOCIDO COMO AB122 O GS-0122) Y ZIMBERELIMAB SOLO PARA EL TRATAMIENTO DE DIFERENTES TIPOS DE CÁNCER.
Technical Summary
- A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF GS-1811, AN AFUCOSYLATED ANTI-CCR8 MONOCLONAL ANTIBODY, AS MONOTHERAPY AND IN COMBINATION WITH AN ANTI¿PD-1 MONOCLONAL ANTIBODY IN ADULTS WITH ADVANCED SOLID TUMORS
- Code EudraCT: -
- Protocol number: GS-US-570-6015
- Promoter: Gilead Science
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.